Coverage
-
December 16, 2013
A New Jersey federal judge on Friday barred Mylan Inc. from manufacturing, importing or selling its own version of Teva Pharmaceutical Industries Ltd.'s brand-name treatment for Parkinson's disease, Azilect, for more than three years, after the generic-drug maker stipulated its proposed generic infringed a Teva patent.
6 other articles on this case.
View all »